A cell autonomous role for the Notch ligand Delta-like 3 in αβ T- cell development

Notch signalling is critical to help direct T-cell lineage commitment in early T-cell progenitors and in the development of αβ T-cells. Epithelial and stromal cell populations in the thymus express the Notch DSL (Delta, Serrate and Lag2) ligands Delta-like 1 (Dll1), Delta-like 4 (Dll4), Jagged 1 and Jagged 2, and induce Notch signalling in thymocytes that express the Notch receptor. At present there is nothing known about the role of the Delta-like 3 (Dll3) ligand in the immune system. Here we describe a novel cell autonomous role for Dll3 in αβ T-cell development. We show that Dll3 cannot activate Notch when expressed in trans but like other Notch ligands it can inhibit Notch signalling when expressed in cis with the receptor. The loss of Dll3 leads to an increase in Hes5 expression in double positive thymocytes and their increased production of mature CD4+ and CD8+ T cells. Studies using competitive irradiation chimeras proved that Dll3 acts in a cell autonomous manner to regulate positive selection but not negative selection of autoreactive T cells. Our results indicate that Dll3 has a unique function during T-cell development that is distinct from the role played by the other DSL ligands of Notch and is in keeping with other recent studies indicating that Dll1 and Dll3 ligands have non-overlapping roles during embryonic development

Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation

<p>Abstract</p> <p>Background</p> <p>Human growth factor receptor bound protein 7 (Grb7) is an adapter protein that mediates the coupling of tyrosine kinases with their downstream signaling pathways. Grb7 is frequently overexpressed in invasive and metastatic human cancers and is implicated in cancer progression via its interaction with the ErbB2 receptor and focal adhesion kinase (FAK) that play critical roles in cell proliferation and migration. It is thus a prime target for the development of novel anti-cancer therapies. Recently, an inhibitory peptide (G7-18NATE) has been developed which binds specifically to the Grb7 SH2 domain and is able to attenuate cancer cell proliferation and migration in various cancer cell lines.</p> <p>Results</p> <p>As a first step towards understanding how Grb7 may be inhibited by G7-18NATE, we solved the crystal structure of the Grb7 SH2 domain to 2.1 Å resolution. We describe the details of the peptide binding site underlying target specificity, as well as the dimer interface of Grb 7 SH2. Dimer formation of Grb7 was determined to be in the μM range using analytical ultracentrifugation for both full-length Grb7 and the SH2 domain alone, suggesting the SH2 domain forms the basis of a physiological dimer. ITC measurements of the interaction of the G7-18NATE peptide with the Grb7 SH2 domain revealed that it binds with a binding affinity of K_d= ~35.7 μM and NMR spectroscopy titration experiments revealed that peptide binding causes perturbations to both the ligand binding surface of the Grb7 SH2 domain as well as to the dimer interface, suggesting that dimerisation of Grb7 is impacted on by peptide binding.</p> <p>Conclusion</p> <p>Together the data allow us to propose a model of the Grb7 SH2 domain/G7-18NATE interaction and to rationalize the basis for the observed binding specificity and affinity. We propose that the current study will assist with the development of second generation Grb7 SH2 domain inhibitors, potentially leading to novel inhibitors of cancer cell migration and invasion.</p

Bemestingsproef met stikstof en met kali : resultaten van de derde teelt chrysanten (1973)

<p><b>Copyright information:</b></p><p>Taken from "Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation"</p><p>http://www.biomedcentral.com/1472-6807/7/58</p><p>BMC Structural Biology 2007;7():58-58.</p><p>Published online 25 Sep 2007</p><p>PMCID:PMC2131756.</p><p></p>ture elements present in the Grb7 SH2 structure as determined by WHATIF [71] are shaded from purple at the N-terminus to red at the C-terminus. Secondary structure elements of the canonical SH2 domain as defined by Eck . [41] are shown in green and orange symbols above the sequences. The boundaries of these elements differ slightly from that observed in the Grb7 SH2 domain. Residue number is for the Grb7 SH2 domain (b) Cartoon representation of the Grb7 SH2 domain shaded from purple at the N-terminus to red at the C-terminus. The extended DE loop distinguishes this family of SH2 domains from others. (c) A structural comparison of the Grb7 SH2 domain (green) with the Grb7 SH2 domain bound to an ErbB2 derived phosphopeptide (1MW4; black; [29]). The location of the bound phosphopeptide is indicated

A cell autonomous role for the Notch ligand Delta-like 3 in αβ T-cell development

Notch signalling is critical to help direct T-cell lineage commitment in early T-cell progenitors and in the development of αΒ T-cells. Epithelial and stromal cell populations in the thymus express the Notch DSL (Delta, Serrate and Lag2)ligands Delta-l

The solution structure and intramolecular associations of the Tec kinase Src homology 3 domain

Journal of Biological Chemistry, Vol. 277, No. 1, Issue of January 4, pp. 755–762, 2002 © 2002 by The American Society for Biochemistry and Molecular BiologyTec is the prototypic member of a family of intracellular tyrosine kinases that includes Txk, Bmx, Itk, and Btk. Tec family kinases share similarities in domain structure with Src family kinases, but one of the features that differentiates them is a proline-rich region (PRR) preceding their Src homology (SH) 3 domain. Evidence that the PRR of Itk can bind in an intramolecular fashion to its SH3 domain and the lack of a regulatory tyrosine in the C terminus indicates that Tec kinases must be regulated by a different set of intramolecular interactions to the Src kinases. We have determined the solution structure of the Tec SH3 domain and have investigated interactions with its PRR, which contains two SH3-binding sites. We demonstrate that in vitro, the Tec PRR can bind in an intramolecular fashion to the SH3. However, the affinity is lower than that for dimerization via reciprocal PRR-SH3 association. Using site-directed mutagenesis we show that both sites can bind the Tec SH3 domain; site 1 (155KTLPPAP161) binds intramolecularly, while site 2 (165KRRPPPPIPP174) cannot and binds in an intermolecular fashion. These distinct roles for the SH3 binding sites in Tec family kinases could be important for protein targeting and enzyme activation.Sharon E. Pursglove, Terrence D. Mulhern, Joel P. Mackay, Mark G. Hinds, and Grant W. Booke

Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation-7

<p><b>Copyright information:</b></p><p>Taken from "Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation"</p><p>http://www.biomedcentral.com/1472-6807/7/58</p><p>BMC Structural Biology 2007;7():58-58.</p><p>Published online 25 Sep 2007</p><p>PMCID:PMC2131756.</p><p></p>ture elements present in the Grb7 SH2 structure as determined by WHATIF [71] are shaded from purple at the N-terminus to red at the C-terminus. Secondary structure elements of the canonical SH2 domain as defined by Eck . [41] are shown in green and orange symbols above the sequences. The boundaries of these elements differ slightly from that observed in the Grb7 SH2 domain. Residue number is for the Grb7 SH2 domain (b) Cartoon representation of the Grb7 SH2 domain shaded from purple at the N-terminus to red at the C-terminus. The extended DE loop distinguishes this family of SH2 domains from others. (c) A structural comparison of the Grb7 SH2 domain (green) with the Grb7 SH2 domain bound to an ErbB2 derived phosphopeptide (1MW4; black; [29]). The location of the bound phosphopeptide is indicated

Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation-1

<p><b>Copyright information:</b></p><p>Taken from "Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation"</p><p>http://www.biomedcentral.com/1472-6807/7/58</p><p>BMC Structural Biology 2007;7():58-58.</p><p>Published online 25 Sep 2007</p><p>PMCID:PMC2131756.</p><p></p>l is coloured blue and negatively charged electrostatic potential is coloured red. The positions of the phosphate binding pocket is indicated. (b) A 2F- Felectron density map depicting the phosphate binding pocket of Grb7 SH2. A sulphate ion co-crystallised in this pocket in all four molecules in the asymmetric unit. The map is contoured at 1 σ. R438, R458, Q461 and S460 form direct contacts with the sulphate ion and are labeled. The side-chain of R462 lacks well defined density and is probably fairly mobile in the crystal

Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation-3

<p><b>Copyright information:</b></p><p>Taken from "Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation"</p><p>http://www.biomedcentral.com/1472-6807/7/58</p><p>BMC Structural Biology 2007;7():58-58.</p><p>Published online 25 Sep 2007</p><p>PMCID:PMC2131756.</p><p></p>ion of 36 μM. The data collected at 14,000 rpm (), 16,600 rpm (), 24,300 rpm () and 28,800 rpm () were fitted simultaneously using the nonlinear regression program [48]. (b) Absorbance at 280 nm verses radius data at sedimentation equilibrium for Grb7 at an initial loading concentrations of 12 μM. The data collected at 10,000 rpm () and 11,800 rpm () were fitted simultaneously using the nonlinear regression program NONLIN [77]. The represents the calculated fit to a monomer-dimer model. The residuals of the fit are shown in the . Samples were in 50 mM MES pH 6.6, 100 mM NaCl and 1 mM DTT. The experiments were conducted at 20°C

Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation-0

<p><b>Copyright information:</b></p><p>Taken from "Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation"</p><p>http://www.biomedcentral.com/1472-6807/7/58</p><p>BMC Structural Biology 2007;7():58-58.</p><p>Published online 25 Sep 2007</p><p>PMCID:PMC2131756.</p><p></p>ture elements present in the Grb7 SH2 structure as determined by WHATIF [71] are shaded from purple at the N-terminus to red at the C-terminus. Secondary structure elements of the canonical SH2 domain as defined by Eck . [41] are shown in green and orange symbols above the sequences. The boundaries of these elements differ slightly from that observed in the Grb7 SH2 domain. Residue number is for the Grb7 SH2 domain (b) Cartoon representation of the Grb7 SH2 domain shaded from purple at the N-terminus to red at the C-terminus. The extended DE loop distinguishes this family of SH2 domains from others. (c) A structural comparison of the Grb7 SH2 domain (green) with the Grb7 SH2 domain bound to an ErbB2 derived phosphopeptide (1MW4; black; [29]). The location of the bound phosphopeptide is indicated